Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 6/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | GAA | P10253 | 3/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11814225 | 0.91 | KMT2A (0.83) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11515272 | 0.87 | KMT2A (0.77) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11757368 | 0.84 | SMN1; SMN2 (0.78) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11514074 | 0.84 | KMT2A (0.73) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11512166 | 0.83 | KMT2A (0.71) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11755573 | 0.83 | KMT2A (0.71) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11808136 | 0.83 | KMT2A (0.71) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL31388347 | 0.82 | KMT2A (0.71) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11770005 | 0.82 | KMT2A (0.69) | KMT2AMEN1ALOX12ALDH1A1LMNA | |
| SCHEMBL11808705 | 0.81 | KMT2A (0.68) | KMT2AMEN1ALOX12ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3950538-A | Anti-inflammatory methods utilizing certain thioureas | THE DOW CHEMICAL COMPANY (US) | 1976-04-13 | — | — | US | claimed |
| US-20070040151-A1 | Two-component initiator system (amine-free) with very good storage stability and particular suitability for acid systems | HERAEUS KULZER GMBH (DE) | 2007-02-22 | — | — | US | disclosed |
| US-7053114-B2 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-6797725-B2 | SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS | SUGEN, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2002081466-A1 | PRODRUGS OF 3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES | SUGEN, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-4009284-A | Gastrointestinally active thioureas | ROHM AND HAAS COMPANY (US) | 1977-02-22 | — | — | US | disclosed |
| US-3975433-A | ANTIDEPRESSANT, PARASITICIDE | THE DOW CHEMICAL COMPANY (US) | 1976-08-17 | — | — | US | disclosed |
| US-3950538-A | Anti-inflammatory methods utilizing certain thioureas | THE DOW CHEMICAL COMPANY (US) | 1976-04-13 | — | — | US | disclosed |
| US-3950537-A | Gastrointestinally active thioureas | ROHM AND HAAS COMPANY (US) | 1976-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | KMT2A 1772/4885MEN1 3621/4885ALOX12 4602/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | KMT2A 1772/4885MEN1 3621/4885ALOX12 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.